Cargando…

Yokukansan, a Kampo Medicine, Protects PC12 Cells from Glutamate-Induced Death by Augmenting Gene Expression of Cystine/Glutamate Antiporter System Xc(−)

Effects of the kampo medicine yokukansan on gene expression of the cystine/glutamate antiporter system Xc(−), which protects against glutamate-induced cytotoxicity, were examined in Pheochromocytoma cells (PC12 cells). Yokukansan inhibited glutamate-induced PC12 cell death. Similar cytoprotective ef...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanno, Hitomi, Kawakami, Zenji, Mizoguchi, Kazushige, Ikarashi, Yasushi, Kase, Yoshio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2014
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4281137/ https://www.ncbi.nlm.nih.gov/pubmed/25551766 http://dx.doi.org/10.1371/journal.pone.0116275

Ejemplares similares

Comparison of the Effects of Yokukansan and Yokukansankachimpihange on Glutamate Uptake by Cultured Astrocytes and Glutamate-Induced Excitotoxicity in Cultured PC12 Cells
por: Kawakami, Zenji, et al.
Publicado: (2019)

The System xc- Cystine/Glutamate Antiporter: An Exciting Target for Antiepileptogenic Therapy?
por: Gallagher, Martin
Publicado: (2020)

Basic Study of Drug-Drug Interaction between Memantine and the Traditional Japanese Kampo Medicine Yokukansan
por: Matsumoto, Takashi, et al.
Publicado: (2018)

Molecular basis for redox control by the human cystine/glutamate antiporter system xc(−)
por: Parker, Joanne L., et al.
Publicado: (2021)

Yokukansan, a Traditional Japanese Medicine, Enhances the Glutamate Transporter GLT-1 Function in Cultured Rat Cortical Astrocytes
por: Ueki, Toshiyuki, et al.
Publicado: (2018)

Cellular Pharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan on Brain Cells
por: Mizoguchi, Kazushige, et al.
Publicado: (2017)

Multiple Psychopharmacological Effects of the Traditional Japanese Kampo Medicine Yokukansan, and the Brain Regions it Affects
por: Mizoguchi, Kazushige, et al.
Publicado: (2017)

[(18)F]FSPG-PET reveals increased cystine/glutamate antiporter (xc-) activity in a mouse model of multiple sclerosis
por: Hoehne, Aileen, et al.
Publicado: (2018)

Increased expression of cystine/glutamate antiporter in multiple sclerosis
por: Pampliega, Olatz, et al.
Publicado: (2011)

Change of cystine/glutamate antiporter expression in ethanol-dependent rats
por: Peana, Alessandra T., et al.
Publicado: (2014)

Identification, Expression, and Roles of the Cystine/Glutamate Antiporter in Ocular Tissues
por: Martis, Renita M., et al.
Publicado: (2020)

Specific Binding and Characteristics of 18β-Glycyrrhetinic Acid in Rat Brain
por: Mizoguchi, Kazushige, et al.
Publicado: (2014)

High-Throughput Assay Development for Cystine-Glutamate Antiporter (x(c) (-)) Highlights Faster Cystine Uptake than Glutamate Release in Glioma Cells
por: Thomas, Ajit G., et al.
Publicado: (2015)

Corticostriatal dysfunction and social interaction deficits in mice lacking the cystine/glutamate antiporter
por: Bentea, Eduard, et al.
Publicado: (2020)

Cystine/Glutamate Antiporter in Schizophrenia: From Molecular Mechanism to Novel Biomarker and Treatment
por: Hung, Chung-Chieh, et al.
Publicado: (2021)

Early Onset of Age-Related Cataracts in Cystine/Glutamate Antiporter Knockout Mice
por: Martis, Renita Maria, et al.
Publicado: (2021)

The glutamate/cystine xCT antiporter antagonizes glutamine metabolism and reduces nutrient flexibility
por: Shin, Chun-Shik, et al.
Publicado: (2017)

Cystine/glutamate antiporter System x(c)(-) deficiency impairs insulin secretion in mice
por: de Baat, Axel, et al.
Publicado: (2023)

Yokukansan Increases 5-HT(1A) Receptors in the Prefrontal Cortex and Enhances 5-HT(1A) Receptor Agonist-Induced Behavioral Responses in Socially Isolated Mice
por: Ueki, Toshiyuki, et al.
Publicado: (2015)

The cystine/glutamate antiporter system x(c)(−) drives breast tumor cell glutamate release and cancer-induced bone pain
por: Slosky, Lauren M., et al.
Publicado: (2016)

Implication of the glutamate–cystine antiporter xCT in schizophrenia cases linked to impaired GSH synthesis
por: Fournier, M., et al.
Publicado: (2017)

Cystine/Glutamate Antiporter (xCT) Is Required for Chief Cell Plasticity After Gastric Injury
por: Meyer, Anne R., et al.
Publicado: (2019)

The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer
por: Jyotsana, Nidhi, et al.
Publicado: (2022)

Yokukansan and Yokukansankachimpihange Ameliorate Aggressive Behaviors in Rats with Cholinergic Degeneration in the Nucleus Basalis of Meynert
por: Tabuchi, Masahiro, et al.
Publicado: (2017)

Cystine/Glutamate Antiporter and Aripiprazole Compensate NMDA Antagonist-Induced Dysfunction of Thalamocortical L-Glutamatergic Transmission
por: Fukuyama, Kouji, et al.
Publicado: (2018)

Cystine–glutamate antiporter xCT deficiency suppresses tumor growth while preserving antitumor immunity
por: Arensman, Michael D., et al.
Publicado: (2019)

Iron dyshomeostasis, lipid peroxidation and perturbed expression of cystine/glutamate antiporter in Alzheimer’s disease: Evidence of ferroptosis
por: Ashraf, Azhaar, et al.
Publicado: (2020)

Cystine/Glutamate antiporter system x(c)(-) deficiency impairs macrophage glutathione metabolism and cytokine production
por: de Baat, Axel, et al.
Publicado: (2023)

The Effect of the Kampo Medicine Yokukansan on Preoperative Anxiety and Sedation Levels
por: Arai, Young-Chang, et al.
Publicado: (2014)

The x(c)(−) cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance
por: Lo, M, et al.
Publicado: (2008)

Analysis of DNA methylation associates the cystine–glutamate antiporter SLC7A11 with risk of Parkinson’s disease
por: Vallerga, Costanza L., et al.
Publicado: (2020)

Cystine–glutamate antiporter deletion accelerates motor recovery and improves histological outcomes following spinal cord injury in mice
por: Sprimont, Lindsay, et al.
Publicado: (2021)

Immunotherapy against the Cystine/Glutamate Antiporter xCT Improves the Efficacy of APR-246 in Preclinical Breast Cancer Models
por: Barutello, Giuseppina, et al.
Publicado: (2022)

The Cystine/Glutamate Antiporter, System x(c)(–), Contributes to Cortical Infarction After Moderate but Not Severe Focal Cerebral Ischemia in Mice
por: He, Yan, et al.
Publicado: (2022)

Structural investigation of human cystine/glutamate antiporter system x(c) (−) (Sx(c) (−)) using homology modeling and molecular dynamics
por: Hang, Tran Dieu, et al.
Publicado: (2022)

Symport and antiport mechanisms of human glutamate transporters
por: Qiu, Biao, et al.
Publicado: (2023)

Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma
por: Nagane, Masaki, et al.
Publicado: (2018)

Cystine/glutamate antiporter xCT (SLC7A11) facilitates oncogenic RAS transformation by preserving intracellular redox balance
por: Lim, Jonathan K. M., et al.
Publicado: (2019)

Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells
por: Hasegawa, Masanori, et al.
Publicado: (2016)

Diagnosing Alzheimer’s Disease Specifically and Sensitively With pLG72 and Cystine/Glutamate Antiporter SLC7A11 AS Blood Biomarkers
por: Lane, Hsien-Yuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_nmiflm5k458agcmtl3ab2al3rc